Clinical Trial

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to find out how significantly Eloralintide slows stomach emptying in participants who are overweight or obese. For each participant, the study will last approximately 21 weeks and will include 2 overnight stays in the clinical research unit (CRU) lasting between 4 and 8 days. There will be 13 other visits.
Trial Details
NCT Number NCT07738614
Lead Sponsor Eli Lilly and Company
Conditions Obesity, Overweight
Enrollment 56 participants
Start Date 2026-07
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-31